Eltrombopag olamine is a thrombopoietin receptor agonist primarily used to treat low blood platelet counts in adults with chronic immune thrombocytopenia, particularly when other therapies or splenectomy… Read more





Eltrombopag olamine is a thrombopoietin receptor agonist primarily used to treat low blood platelet counts in adults with chronic immune thrombocytopenia, particularly when other therapies or splenectomy have proven ineffective, and for thrombocytopenia in patients with chronic hepatitis C. This category provides essential pharmaceutical reference standards for Eltrombopag olamine, including pharmacopeial and non-pharmacopeial impurities such as the N-oxide derivative and dimer, as well as specific metabolites and stable isotope labelled compounds. Pharmaceutical laboratories utilize these high-quality materials for impurity profiling, method validation, and rigorous quality control testing of the drug substance. By providing access to these specialized compounds, researchers and analysts can ensure the accuracy of analytical procedures and confirm the integrity of the active pharmaceutical ingredient throughout the drug development and manufacturing lifecycle.